Is Alector, Inc. (ALEC) a Buy, Sell, or Hold?
Alector, Inc.
NASDAQ:ALEC
$1.5 USD
$0.11 (7.91%)
- Volume
- 718.78K
- Average Volume
- 722.22K
- Market Capitalization
- $166.54M
- P/E Ratio
- -1.26
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $3.40
- Year Low
- $1.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.25
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Arnon Rosenthal |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALEC |
| CUSIP | 014442107 |
| CIK | 0001653087 |
| Web | https://www.alector.com |
| Phone | 415 231 5660 |
| Currency | USD |
| Employees | 103 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.33 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.25 |
| Quick Ratio | 5.25 |
| Cash Ratio | 1.88 |
Sales & Book Value
| Annual Sales | $21.04M |
| Price / Sales | 9.04 |
| Cash Flow | -1.57 |
| Price / Cash Flow | -0.96 |
| Price / Book | 15.98 |
Price Target and Rating
| Average Stock Price Forecast | $2.00 |
| High Stock Price Forecast | $2.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -25.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.39 |
| Trailing P/E Ratio | -1.26 |
| PEG Ratio | 0.21 |
| P/E Growth | 0.21 |
| Net Income | $-142.93M |
| Net Margin | -680.83% |
| Pretax Margin | -679.92% |
| Return on Equity | -295.17% |
| Return on Assets | -52.26% |
Financials Score
| AltmanZ Score | -6.15 |
| Piotroski Score | 3.00 |
| Working Capital | 174.12M |
| Total Assets | 239.92M |
| Ebit | -125.22M |
| Market Cap | 166.54M |
| Total Liabilities | 229.53M |
Poll Results
About Alector, Inc. (NASDAQ:ALEC) Stock
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA. ...
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
2026-07-08 17:20:31
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 20:12:11
Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago.
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 16:05:00
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
2026-05-07 11:00:51
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2026-04-29 16:05:00
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease (AD) will be discontinued.
Frequently Asked Questions
-
What is the current Alector, Inc. (ALEC) stock price?
-
Alector, Inc.(NASDAQ:ALEC) stock price is $1.5 in the last trading session. During the trading session, ALEC stock reached the peak price of $3.4 while $1.09 was the lowest point it dropped to. The percentage change in ALEC stock occurred in the recent session was 7.91% while the dollar amount for the price change in ALEC stock was $0.11.
-
ALEC's industry and sector of operation?
-
The NASDAQ listed ALEC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALEC?
-
Hua Long DABT | Senior VP & Head of Research
Clare Hunt | Chief People & Places Officer
Katie Hogan | Senior Director of Corporate Communication & Investor Relations
Giacomo Salvadore | Chief Medical Officer
Kristina Cutter | Chief Development Officer -
How many employees does ALEC have?
-
Number of ALEC employees currently stands at 103. ALEC operates from 131 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for ALEC official website?
-
Official Website of ALEC is: https://www.alector.com
-
How do I contact ALEC?
-
ALEC could be contacted at phone #415 231 5660 and can also be accessed through its website. ALEC operates from 131 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of ALEC are traded daily?
-
The average number of ALEC shares traded daily for last 3 months was 722.22K.
-
What is the market cap of ALEC currently?
-
The market value of ALEC currently stands at $166.54M with its latest stock price at $1.5